Recherche
Résultats 41-50 de 188
-
Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France
European Journal of Cancer, Elsevier, 03-2016, 58, 90-96Article dans une revue scientifique -
2015 through the eyes of the Bulletin of Cancer editorial board
Bulletin du Cancer, John Libbey Eurotext, 01-2016, 103 (1769-6917), 3-17Article dans une revue scientifique -
Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the french sarcoma group
European journal of cancer (Oxford, England . 1990), 01-04-2015, 51, 742-750Article dans une revue scientifique -
How to report toxicity associated with targeted therapies?
Annals of oncology . official journal of the European Society for Medical Oncology, 01-08-2016, 27, 1633-1638Article dans une revue scientifique -
Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet. Oncology, 01-05-2015, 16, 531-540Article dans une revue scientifique -
Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial
BMC Cancer, 11-10-2018, 18, 963Article dans une revue scientifiquetexte intégral -
Anti-pld1 and anti-pd1 in advanced urothelial cancers: promises from early phase trials
Bulletin du cancer, 01-10-2016, 103, 811-812Article dans une revue scientifique -
Eribulin in the soft tissue sarcoma therapeutic landscape: little is good, then more is better
Translational cancer research, 01-11-2016, 5, S1160-S1162Article dans une revue scientifique -
Targeting angiogenesis in advanced soft tissue sarcoma: tivozanib - hype or me-too?
Annals of oncology . official journal of the European Society for Medical Oncology, 01-01-2017, 28, 13-15Article dans une revue scientifique -
Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (t-dis): a randomised phase 2 trial
The Lancet. Oncology, 01-03-2015, 16, 312-319Article dans une revue scientifique